PERCEPTIVE ADVISORS LLC Acquires Significant Stake in SAB Biotherapeutics Inc, Boosting Biotech Portfolio

Perceptive Advisors LLC acquired 3.47 million shares of SAB Biotherapeutics Inc at $4 per share, marking a strategic move in the biotechnology sector. The acquisition represents a 0.4% impact on Perceptive Advisors' portfolio and positions SAB Biotherapeutics as 7.3% of the firm's holdings. SAB Biotherapeutics has a market capitalization of $209.9 million and has experienced a 10.25% gain since the transaction, contributing to a year-to-date price change of 16.98%.